California Affordable Drug Manufacturing Act of 2020: opioid antagonists.
Impact
If enacted, AB 1320 would impose significant constraints on how state agencies conduct their procurement processes, particularly in relation to opioid antagonists. By nullifying any contracts made in violation of this provision and making such contracts retroactively unenforceable back to January 1, 2026, the bill aims to promote accountability among contractors involved in the opioid crisis. This would not only affect existing contracts but also reshape future dealings between state agencies and pharmaceutical providers, fostering an environment that prioritizes ethical practices in procurement.
Summary
Assembly Bill 1320, introduced by Assembly Member Patterson, amends the California Health and Safety Code by adding Section 127698. This legislation is designed to address contracting practices related to the procurement of opioid antagonists, such as naloxone. Under this bill, state agencies are prohibited from awarding contracts on a noncompetitive basis for the acquisition of an opioid antagonist from any contractor that has entered into a multistate settlement agreement concerning its contributions to the opioid crisis. This is aimed at ensuring that state agencies do not partner with companies that have been implicated in the opioid epidemic.
Contention
Notably, the bill addresses mounting public concern regarding the role of pharmaceutical companies in the opioid epidemic. The prohibition against contracting with companies that have reached settlements signifies a proactive legislative measure, seeking to reduce the state's reliance on entities that have played a role in perpetuating drug addiction. However, there may be debate around the practicality of the measure, as it could limit the pool of available contractors, potentially impacting the state's ability to procure essential medications in a timely manner.